COST-EFFECTIVENESS OF USING DAPAGLIFLOZIN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION: A PHARMACOECONOMIC MODEL ANALYSIS

被引：0
|
作者：
Cavusoglu, Y. [1 ]
Demir, O. [2 ]
Dinc, M. [3 ]
Ozsoy, A. [3 ]
Erdogan, A. [3 ]
Ozer, S. [4 ]
机构：
[1] Eskisehir Osmangazi Univ, Fac Med, Istanbul 34, Turkey
[2] Ankara Univ, Fac Med, Ankara, Turkey
[3] AstraZeneca, Istanbul, Turkey
[4] Omega CRO, Ankara, Turkey
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSA166
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN HEART FAILURE WITH REDUCED LEFT VENTRICULAR EJECTION FRACTION IN SPAIN
    Fernandez de Bobadilla, J.
    Gonzalez Fernandez, O.
    Lopez de Sa, E.
    Lopez-Sendon, J. L.
    VALUE IN HEALTH, 2014, 17 (07) : A486 - A486
  • [42] Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: A cost-effectiveness analysis
    Rane, Amey
    Nechi, Regina Nwamaka
    Imam, Maryam
    Zoni, Cesar Rodrigo
    Ndikumukiza, Cyrille
    Karaye, Ibraheem M.
    Yunusa, Ismaeel
    Alanzi, Abdullah
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (09): : 1045 - 1053
  • [43] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF SYMPTOMATIC CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL
    Alarcao, J.
    Ascencao, R.
    Costa, J.
    Gouveia, M.
    Borges, M.
    VALUE IN HEALTH, 2018, 21 : S104 - S104
  • [44] Projected effectiveness of dapagliflozin in heart failure with reduced ejection fraction in clinical practice
    Montero-Perez-Barquero, Manuel
    Escobar-Cervantes, Carlos
    Arevalo-Lorido, Jose Carlos
    Conde-Martel, Alicia
    Salamanca-Bautista, Prado
    Manzano-Espinosa, Luis
    Formiga, Francesc
    Diez-Manglano, Jesus
    Cepeda, Jose Maria
    Gonzalez-Franco, Alvaro
    Casado-Cerrada, Jesus
    FUTURE CARDIOLOGY, 2023, 19 (06) : 343 - 351
  • [45] COST-EFFECTIVENESS ANALYSIS OF PATIROMER IN HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION FOR THE TREATMENT OF HYPERKALEMIA: ANALYSIS OF THE DIAMOND CLINICAL TRIAL
    Stawowczyk, E.
    Turner, M.
    Lewis, R. D.
    Lloyd, I. T.
    Ruiz, O.
    Serna, Ramirez De Arellano A.
    VALUE IN HEALTH, 2023, 26 (12) : S139 - S139
  • [46] Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction
    Sandhu, Alexander T.
    Ollendorf, Daniel A.
    Chapman, Richard H.
    Pearson, Steven D.
    Heidenreich, Paul A.
    ANNALS OF INTERNAL MEDICINE, 2016, 165 (10) : 681 - +
  • [47] A NEW COST-EFFECTIVENESS MODELLING APPROACH IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
    McMurray, J. J.
    Cowie, M. R.
    Cohen, A. A.
    Briggs, A.
    de Pouvourville, G.
    Taylor, M.
    Hancock, E.
    Trueman, D.
    Mumby-Croft, J.
    Haroun, R.
    Deschaseaux, C.
    VALUE IN HEALTH, 2015, 18 (07) : A394 - A394
  • [48] Cost-effectiveness of quadruple therapy for heart failure with reduced ejection fraction (HFrEF) in Spain
    Garcia-Quintana, A.
    Javier Parrondo, J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 84 - 85
  • [49] Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction
    Dixit, Neal M.
    Truong, Katie P.
    Vaduganathan, Muthiah
    Ziaeian, Boback
    Fonarow, Gregg C.
    JACC-HEART FAILURE, 2024, 12 (07) : 1226 - 1237
  • [50] Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction
    Gaziano, Thomas A.
    Fonarow, Gregg C.
    Claggett, Brian
    Chan, Wing W.
    Deschaseaux-Voinet, Celine
    Turner, Stuart J.
    Rouleau, Jean L.
    Zile, Michael R.
    McMurray, John J. V.
    Solomon, Scott D.
    JAMA CARDIOLOGY, 2016, 1 (06) : 666 - 672
12345